RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MICHELOTTI A
Collezione AO Cuneo

Items : 3

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. in Scientific reports / Sci Rep. 2021 Jul 2;11(1):13770. doi: 10.1038/s41598-021-92774-z.

2021
AO Cuneo

Pizzuti L; Barba M; Mazzotta M; Krasniqi E; Maugeri-Saccà M; Gamucci T; Berardi R; Livi L; Ficorella C; Natoli C; Cortesi E; Generali D; La Verde N; Cassano A; Bria E; Moscetti L; Michelotti A; Adamo V; Zamagni C; Tonini G; Sergi D; Marinelli D; Paoletti G; Tomao S; Botticelli A; Marchetti P; Tinari N; Grassadonia A; Valerio MR; et alii...

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. in Journal of experimental & clinical cancer research : CR / J Exp Clin Cancer Res. 2020 Dec 10;39(1):279. doi: 10.1186/s13046-020-01797-3.

2020
AO Cuneo

Del Medico P; Cazzaniga M; Garufi C; Sarobba G; Giotta F; Paris I; Garrone O; Veltri E; Corsi D; D'Ostilio N; Fabbri MA; Russo A; Mirabelli R; Valerio MR; Marchetti P; Tomao S; Marinelli D; Mazzotta M; Barchiesi G; Zamagni C; Tonini G; Adamo V; Michelotti A; Moscetti L; Bria E; Cassano A; La Verde N; Generali D; Cortesi E; et alii...

5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. in Breast cancer research and treatment / Breast Cancer Res Treat. 2016 Jan;155(1):117-26. doi: 10.1007/s10549-015-3655-1. Epub 2015 Dec 10.

2016
AO Cuneo

Del Mastro L; Levaggi A; Michelotti A; Cavazzini G; Adami F; Scotto T; Piras M; Danese S; Garrone O; Durando A; Accortanzo V; Bighin C; Miglietta L; Pastorino S; Pronzato P; Castiglione F; Landucci E; Conte P; Bruzzi P;